Answers are grounded in this paper and cite their sources.
Preclinical study reveals that omentin-1 suppresses joint degradation and inflammation in osteoarthritis models, highlighting its potential as a targeted disease-modifying therapeutic.
Osteoarthritis (OA) is a prevalent joint disease commonly associated with aging and obesity, which can lead to pain, stiffness, joint dysfunction, and disability.Omentin-1 (also called intelectin-1) is a newly discovered adipokine, which plays a protective role in suppressing the secretion of pro-inflammatory cytokines.Based on data from the Gene Expression Omnibus (GEO) dataset and clinical samples obtained at our institution revealed, determined that omentin-1 and IL-4 (an anti-inflammatory cytokine) levels were significantly lower in OA patients than in normal controls.Omentin-1 was shown to induce IL-4-depedent anti-inflammatory responses and M2 macrophage polarization in OA synovial fibroblasts via the PI3K, ERK, and AMPK pathways.Administering omentin-1 was shown to block cartilage degradation and bone erosion resulting from anterior cruciate ligament transection by inhibiting the production of pro-inflammatory cytokines and promoting M2 macrophage polarization in vivo.Our findings indicate omentin-1 as a promising therapeutic avenue for the treatment for OA.
No takes yet. Share an insight, caveat, or question.
Ko et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: